Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2022-02-28 Regulatory Filings
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 211.8KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Medical Developments International Limited regarding a trading halt requested pending an announcement about FDA feedback on a clinical hold response. It is dated 1 March 2022 and is relatively short (2800 characters). The content is an official notice to the stock exchange about the trading halt and does not contain financial data, management discussion, or detailed report content. It is not a full report but an announcement related to trading status. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-02-28 English
FY22 Half Year Report and Accounts 23 pages 1.5MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Medical Developments International Limited Appendix 4D' and includes detailed financial data for the half-year ended 31 December 2021, including revenue, net loss, cash balances, and segment performance. It references compliance with ASX Listing Rule 4.2A and 4.2C.3, which relate to half-year financial reporting. The document contains a Directors' Report, Auditor's Independence Declaration, Independent Review Report, Directors' Declaration, and condensed consolidated financial statements such as the Statement of Profit or Loss, Statement of Financial Position, and Notes to the Financial Statements. The presence of comprehensive financial statements and management discussion for a half-year period clearly identifies this as an Interim / Quarterly Report. The document is approximately 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). H1 2022
2022-02-23 English
MVP FY22 Half Year Investor Presentation 9 pages 971.7KB
Interim / Quarterly Report Classification · 95% confidence The document is a presentation containing forward-looking statements, financial highlights for the half year (FY22 H1), sales growth data, EBIT bridge, and updates on plans and investments. It includes detailed financial metrics such as gross revenue, EBIT, net profit/loss, and cash on hand, as well as strategic updates and market performance commentary. The presence of detailed financial data and analysis for a half-year period indicates this is a comprehensive interim or quarterly report rather than a brief announcement or presentation for investors. The document length (7075 characters) and content depth support classification as an Interim / Quarterly Report (IR). H1 2022
2022-02-23 English
MVP FY22 Half Year Investor Presentation 1 page 179
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 22 February 2022 from Medical Developments International Ltd (MVP). It announces the upcoming release of the half year results for the 6 months ended 31 December 2021 (FY22 HY) on 24 August 2022 and invites investors to a live investor presentation on 25 February 2022. The document does not contain the actual half year financial results or substantive financial data but rather informs about the future release and presentation. The document length is short (2025 characters) and it serves as a notice or announcement rather than the report itself. According to the 'MENU VS MEAL' rule, this is an announcement about a report and an invitation to a presentation, not the report or presentation itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2022-02-21 English
MVP concludes CSIRO API Continuous Flow Technology Project 2 pages 192.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 3 February 2022 from Medical Developments International Ltd (MVP). It announces the conclusion of a specific project (CSIRO API Continuous Flow Technology Project) and provides context about the project and future plans. The document is relatively short (3788 characters) and does not contain any financial statements, detailed financial data, or comprehensive report content. It is an update on a project status and a business focus shift, not a full financial report or earnings release. It also mentions a future update with FY22 half year results, indicating this is a standalone announcement rather than a report. There is no indication of voting results, management changes, or regulatory certifications. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit into other specific categories.
2022-02-02 English
Proposed issue of securities - MVP 5 pages 27.1KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Medical Developments International Limited. It details the number and type of securities to be issued, the issue price, the proposed issue date, and compliance with ASX listing rules. There are no financial statements or performance data included, and the document focuses solely on the capital raising activity. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2022-01-09 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.